News Headlines Article

Gilead hepatitis C drugs build road to Japan
San Francisco Business Times

Gilead Sciences Inc. will use this year’s launches of its blockbuster hepatitis C drugs in Japan as springboards for other products in the Asian nation. Leaders of the Foster City-based company aren’t saying much more about which drugs could be next, but it is clear that Japan offers a big opportunity for Gilead’s once-a-day hepatitis C tablets Sovaldi and Harvoni.